tiprankstipranks
Blurbs

Analysts’ Top Healthcare Picks: Aptose Biosciences (APTO), Frequency Therapeutics (FREQ)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aptose Biosciences (APTOResearch Report) and Frequency Therapeutics (FREQResearch Report) with bullish sentiments.

Aptose Biosciences (APTO)

JonesTrading analyst Soumit Roy reiterated a Buy rating on Aptose Biosciences today and set a price target of $8.00. The company’s shares closed last Tuesday at $1.28, close to its 52-week low of $1.00.

According to TipRanks.com, Roy is a 4-star analyst with an average return of 11.5% and a 33.1% success rate. Roy covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Adaptimmune Therapeutics, and Inhibikase Therapeutics.

Aptose Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $9.00, which is a 625.8% upside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $12.00 price target.

See the top stocks recommended by analysts >>

Frequency Therapeutics (FREQ)

B.Riley Financial analyst Mayank Mamtani maintained a Buy rating on Frequency Therapeutics today and set a price target of $10.00. The company’s shares closed last Tuesday at $2.49, close to its 52-week low of $1.62.

According to TipRanks.com, Mamtani is ranked 0 out of 5 stars with an average return of -21.2% and a 28.5% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Madrigal Pharmaceuticals, and Spectrum Pharmaceuticals.

Frequency Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $10.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on APTO:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
---

Latest News Feed